Higher seroreactivity against GroEL was associated with increasing CRC risk (8% higher for each tertile with respect to seronegativity; p = 0.049), and for Cagδ and HP305 higher seroreactivities were associated with decreasing CRC risk: 11% (p < 0.001) and 8% (p = 0.011) lower for each tertile with respect to seronegativity, respectively. Here, HSPD1 is linked to colorectal carcinoma.